Ryan Livingston

Hereditary hemorrhagic telangiectasia has no approved treatments; this designation, in addition to the European Medicines Agency granting a positive opinion, positions DIAG723 to be the first.

Nitisinone is the first and only FDA-approved treatment for AKU, a rare genetic disease without a known cure.

Investigators also noted the risk of Hb overshoot in patients switching from ESA to roxadustat, emphasizing the importance of monitoring Hb levels before and after treatment.

Although limited, recent research has indicated overall positive results of dupilumab in both reducing severe exacerbations and lowering risk of control loss.

New research has indicated increased food tolerance thresholds and desensitization from omalizumab and other biologics in comparison to placebo with no serious adverse effects.

New research has associated complement factors from both the classical and terminal pathways with progression from intermediate to advanced age-related macular degeneration.

Despite the possibility for enhanced stability of IOL rotation and tilt, the potential for ACD increase and a resulting hyperopic refractive shift warrants caution.

The company believes results from a recent phase 3 chamber trial fulfill the FDA’s requests in the Complete Response Letter received in April of 2025.

Recent research comparing the two diseases against a sample of the general population has indicated a substantially higher mortality risk and rate in GPP than in plaque psoriasis.

Research has indicated a suggestive association between predicted psoriasis and uterine corpus cancer in women and prostate cancer in men.

GMRx2 is now the first and only FDA-approved triple combination medication for use as an initial therapy in patients needing multiple drugs to lower blood pressure.

Pseudoexfoliation results in the ganglion cell layer degradation that precedes glaucoma, indicating a potential predictor.

Parent company Amneal Pharmaceuticals, Inc. has announced intentions to launch the topical anti-inflammatory agent in the third quarter of 2025.

An ongoing phase 1 study aims to prove the safety and tolerability of VAS-101, as well as its effect on blood flow dynamics, red blood cell sickling, and oxygen dissociation.

Novartis has announced the safety and efficacy of iptacopan, a twice-daily oral monotherapy for adult patients who switched from eculizumab or ravulizumab.

If approved, mavorixafor will be the second FDA-approved treatment and the first oral medication for CN.

Most modern GDMT components were prescribed to less than half of all patients included in the EMPACE study, indicating the need for strategies to enhance clinical adoption.

Semaglutide’s reduction in systolic blood pressure could indicate more potential for cardiovascular protection than simply its well-known glycemic benefits.

Investigators compared the efficacy of tirzepatide and liraglutide in lowering rates of all-cause mortality in patients with obesity and sleep apnea.

New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea and type 2 diabetes.

These data may upend the typically underperforming CETP inhibitor field with an accessible, oral medication for lowering LDL cholesterol.

GLP-1 RAs, one of the most common medications for obesity and diabetes, have several inherent risks that are often overlooked in favor of their efficacy.

Investigators compared the medications across various patient cohorts with different causes of anemia, finding evidence almost uniformly in favor of FCM.

This recent study highlights the intricate variations between glaucoma cases, encouraging a more individual approach to analyzing treatment responses.

If approved, lamivudine may bring DME treatment and better vision outcomes to communities who cannot afford more costly intravitreal injections.

A recent analysis reveals no significant difference between restrictive and liberal transfusion strategies on quality of life in patients with myocardial infarction and anemia.

A relatively quiet month for hematology, marked by brief ups and downs for trials and new research on anemia and sickle cell disease.

Investigators examined emergency department utilization as a product of age, patient-reported severity of vaso-occlusive episodes, and Social Vulnerability Index score.

This May was characterized by HCPLive’s coverage of the ARVO and Envision conferences, as well as a slew of FDA approvals towards the end of the month.

Vera Therapeutics intends to bring the results before the FDA by the end of 2025; they anticipate an approval and commercial launch in 2026.